ReviewExpert opinion on drug metabolism & toxicology2011
Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.
Review in Expert opinion on drug metabolism & toxicology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02566057 (Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis), which is not on this map. Cited by 74 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis
Who cites it
74 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The genetics of drug-related movement disorders, an umbrella review of meta-analyses.Molecular psychiatry · 2020Pooled it
- Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis.Schizophrenia bulletin · 2016Pooled it
- Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak SubstrateJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Trial
- The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.The pharmacogenomics journal · 2017Trial
- Developing a Polygenic Risk Score for Weight Gain in People Treated for Psychosis-Application in a Real-World Setting.Human psychopharmacology · 2026Article
- Molecular Underpinning of Treatment-Resistant Schizophrenia: A Putative Different Neurobiology from Treatment-Responsive Schizophrenia.International journal of molecular sciences · 2025Review
- Predictive Role of Serotonin Receptor (5HTR2A) and Dopamine Receptor (DRD2) gene polymorphisms in risperidone-induced weight gain and hyperprolactinemia in patients with schizophrenia.European journal of clinical pharmacology · 2025Article
- UnidentifiedJournal of psychopharmacology (Oxford, England) · 2024Article
- Clinical effects of CYP2D6 phenoconversion in patients with psychosis.Journal of psychopharmacology (Oxford, England) · 2024Article
- Pharmacogenetics of Long-Term Outcomes of Schizophrenia Spectrum Disorders: The Functional Role of CYP2D6 and CYP2C19.Journal of personalized medicine · 2023Article
- Dual orexin/hypocretin receptor antagonism attenuates NMDA receptor hypofunction-induced attentional impairments in a rat model of schizophrenia.Behavioural brain research · 2023Article
- Deep Brain Stimulation in the Treatment of Tardive Dyskinesia.Journal of clinical medicine · 2023Review
- Dual orexin/hypocretin receptor antagonism attenuates attentional impairments in an NMDA receptor hypofunction model of schizophrenia.bioRxiv : the preprint server for biology · 2023Article
- Antipsychotic drug-aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms.Pharmacological reports : PR · 2023Review
- Berberine Ameliorate Haloperidol and 3-Nitropropionic Acid-Induced Neurotoxicity in Rats.Neurochemical research · 2022Article
- Polymorphisms in Schizophrenia-Related Genes Are Potential Predictors of Antipsychotic Treatment Resistance and Refractoriness.The international journal of neuropsychopharmacology · 2022Article
- Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Conserved immunomodulatory transcriptional networks underlie antipsychotic-induced weight gain.Translational psychiatry · 2021Article
- Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia.Neuropsychiatric disease and treatment · 2021Article
- Behavioral Tasks Evaluating Schizophrenia-like Symptoms in Animal Models: A Recent Update.Current neuropharmacology · 2021Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
importance of the fieldAntipsychotic drug is the mainstay of treatment for schizophrenia, and there are large inter-individual differences in clinical response and side effects. Pharmacogenetics provides a valuable tool to fulfill the promise of personalized medicine by tailoring treatment based on one's genetic markers. AREAS COVERED IN THIS REVIEW: This article reviews the pharmacogenetic literature from early 1990s to 2010, focusing on two aspects of drug action: pharmacokinetics and pharmacodynamics. Genetic variants in the neurotransmitter receptors including dopamine and 5-HT and metabolic pathways of drugs including CYP2D6 and COMT were discussed in association with clinical drug response and side effects. WHAT THE READER WILL GAIN: Readers are expected to learn the up-to-date evidence in pharmacogenetic research and to gain familiarity to the issues and challenges facing the field. TAKE HOME MESSAGE: Pharmacogenetic research of antipsychotic drugs is both promising and challenging. There is consistent evidence that some genetic variants can affect clinical response and side effects. However, more studies that are designed specifically to test pharmacogenetic hypotheses are clearly needed to advance the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.